Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRAALL-2024: Frontline Therapy of Adults With ALL
NCT06860269Phase 3Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- May 2025
- Primary completion
- Mar 2035
- Modality
- Antibody Conjugates, scFv Fragments, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of blinatumomab, isatuximab, ponatinib in acute lymphoblastic leukemia (ALL), T cell lymphoblastic lymphoma (T-LBL), sponsored by Assistance publique - Hôpitaux de Paris. Started May 2025; status: recruiting.
02
Drugs
blinatumomabisatuximabponatinib
03
Conditions
acute lymphoblastic leukemia (ALL)T cell lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on NCT06860269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06860269.